Infants account for a small proportion of the overall dengue case burden in endemic countries but can be clinically more difficult to manage. The clinical and laboratory features in infants with dengue have not been extensively characterised.
This prospective, cross-sectional descriptive study of infants hospitalized with dengue was conducted in Vietnam from November 2004 to December 2007. More than two-thirds of 303 infants enrolled on clinical suspicion of dengue had a serologically confirmed dengue virus (DENV) infection. Almost all were primary dengue infections and 80% of the infants developed DHF/DSS. At the time of presentation and during hospitalization, the clinical signs and symptoms in infants with dengue were difficult to distinguish from those with other febrile illnesses, suggesting that in infants early laboratory confirmation could assist appropriate management. Detection of plasma NS1 antigen was found to be a sensitive marker of acute dengue in infants with primary infection, especially in the first few days of illness.
Collectively, these results provide a systematic description of the clinical features of dengue in infants and highlight the value of NS1 detection for diagnosis.
Dengue is a major public health problem in tropical and subtropical countries, including Vietnam. Dengue cases occur in children and young adults; however, severe dengue also occurs in infants less than 1 year of age. Prompt recognition of dengue is important for appropriate case management, particularly in infants in whom febrile illness from other causes is common. We describe the clinical picture, virological and immunological characteristics of infants with dengue admitted to three hospitals in southern Vietnam, compared with infants admitted with fever not due to dengue. We show that infants with dengue are difficult to distinguish from those with other febrile illnesses based on signs and symptoms at presentation, and so laboratory tests to confirm dengue virus infection may be useful for diagnosis and management. Conventional diagnostic methods for dengue have low sensitivity early in infection, and we show that an alternative antigen-detection assay that has demonstrated good sensitivity and specificity in older age groups also performs well in infants. This study will help to inform the diagnosis and management of dengue in infants.
Citation: Bich Chau TN, Anders KL, Lien LB, Hung NT, Minh Hieu LT, Tuan NM, et al. (2010) Clinical and Virological Features of Dengue in Vietnamese Infants. PLoS Negl Trop Dis 4(4): e657. doi:10.1371/journal.pntd.0000657
Editor: Scott B. Halstead, Pediatric Dengue Vaccine Initiative, United States of America
Received: November 18, 2009; Accepted: March 2, 2010; Published: April 13, 2010
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This work was supported by the Wellcome Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Dengue represents a substantial disease burden in many tropical and sub-tropical countries, particularly in children and young adults . Infection with any one of the four dengue virus (DENV) serotypes can lead to a sub-clinical infection, or to clinical disease ranging in severity from a non-specific febrile illness to classical dengue fever, dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Severe dengue (DHF/DSS) is strongly associated with secondary heterotypic dengue virus infections in children and adults , , but can also occur in primary DENV infection of infants born to dengue-immune mothers , . Common to these two epidemiological populations are pre-existing DENV-reactive IgG antibodies, which are thought to be a factor in both serotype-specific immunity to infection as well as the pathogenesis of dengue, through a mechanism of antibody-dependent enhancement of infection , .
Previous studies have indicated a low incidence of DENV exposure in infants , , however infants with DHF can be clinically challenging to manage and are at higher risk of mortality than older children , . In dengue-endemic areas infants under one year of age comprise between 1–5% of the dengue cases admitted to hospital each year , , however only a limited number of studies have documented clinical and laboratory findings in infants with dengue , . This evidence indicates that the clinical manifestations of dengue in infants may differ from older children and adults, with a greater frequency of low platelet count (<50000 cells/mm3), plasma leakage and shock and fewer haemorrhagic manifestations in infants compared with dengue in older children , . This paper describes the clinical, hematological and virological characteristics of infants hospitalized with dengue in southern Vietnam. These characteristics were compared to infants hospitalized with other acute febrile illnesses.
Patient recruitment and sample collection
This prospective, descriptive study was conducted at Pediatric Hospitals Number 1 and Number 2, Ho Chi Minh City, and at Dong Thap Hospital, Dong Thap province, Vietnam, from November 2004 to December 2007. Infants under 18 months old with suspected dengue were eligible to be enrolled. Recruitment also took place in the outpatient department of Pediatric Hospital Number 1 from July to December 2005. Written informed consent was obtained from a parent or guardian of each patient. The study was approved by the Scientific and Ethical Committees of the Hospital for Tropical Diseases, Children's Hospital No. 1, Children's Hospital No. 2, and Dong Thap Hospital and Oxford Tropical Research Ethical Committee. Daily venous or capillary blood samples were collected from infants for 4 consecutive days beginning on entry to the study (study day 0), and again 10–14 days after discharge from hospital. Venous blood samples were collected from the mothers of each infant on study day 0 and again 4–8 days later. The extent of hemoconcentration during symptomatic illness was determined by comparing the maximum hematocrit recorded during hospitalization with either the value recorded at follow-up in each patient (47% of cases) or at hospital discharge for those who did not return for follow-up (53% of cases).
Dengue antigen capture IgM and IgG ELISA assays used both inactivated DENV and Japanese encephalitis virus (JEV) antigens and monoclonal anti-DENV antibody provided by Venture Technologies (Sarawak, Malaysia) as previously described . Acute DENV infection was defined as DENV-IgM seroconversion (i.e. from negative to positive) between paired specimens, or rising levels of DENV reactive IgM (at least 20% increase in DENV-IgM ELISA Units from 1st to 2nd sample and 2nd sample has ≥20 ELISA Units). World Health Organization (WHO) classification criteria for disease severity  were applied to each case after reviewing study notes.
DENV viraemia was measured using an internally-controlled, serotype-specific, real-time RT-PCR assay . Results were expressed as cDNA equivalents per milliliter of plasma. DENV NS1 antigen in plasma was measured using the Platelia NS1 assay (BioRad, Hercules, CA) according to the manufacturers' instructions. The concentration of DENV NS1 protein in test plasma samples was quantified by reference to a standard curve, using serial dilutions of immune-affinity purified recombinant DENV-2 NS1 protein (Hawaii Biotechnology Group, Inc). The limit of detection of this test was 5 ng/ml. DENV viraemia and NS1 antigenaemia were measured in samples collected on four consecutive days from study enrolment.
Plaque reduction neutralization test (PRNT)
Neutralizing antibody titres against four reference serotypes (DENV-1 PR/94, DENV-2 NGC, DENV-3 Sleman/76, and DENV-4 814699) in maternal plasma samples were determined by a complement-enhanced PRNT assay as described previously .
Statistical analyses were performed with SPSS version 14. To compare the distribution of categorical variables between patient groups, a chi-squared test for association was used, with p<.05 considered to be statistically significant. For comparison of continuous variables between groups we used a non-parametric test (Mann Whitney U) or, where there were more than two comparison groups, Kruskal-Wallis one-way analysis of variance. We calculated Spearman's rank correlation coefficients (rho) to examine the strength of association between two continuous variables.
Characteristics of the study population
During the study period, we enrolled 293 inpatient infants and young children with suspected dengue and 10 infants treated as outpatients. Seventy-five of these infants have been described previously by our group . The intention of this report is to summarize the main clinical and virological findings in a larger population of infants with dengue. Table 1 shows the demographic characteristics of study participants. Infants' mothers were aged between 19–45 years old (median: 28 yrs), and the infants were aged between 2–18 months old (median: 7 months). The male to female ratio of the infants was 173∶126. The majority of inpatients were enrolled on day 4 or 5 of illness. Sixty-eight percent (204/303) of enrolled infants had serologically confirmed dengue, of which 201 were primary dengue cases and 3 secondary dengue cases. The remaining 99 patients (32%) without serological evidence of dengue were classified as “other febrile illnesses” (OFI). Almost 80% (162/204) of the infants with laboratory confirmed dengue were between 4–10 months old, with the peak at 7–8 months of age.
Clinical characteristics of infants with laboratory-confirmed dengue
Most of the primary dengue cases were classified as DHF grade II (141/201; 70%), with 17% (35/201) classified as DF and 9% (19/201) classified as DSS (DHF III and IV). Five cases could not be classified by the WHO criteria because of insufficient investigations of vascular leakage. Clinical data was not available for one infant. The five infants in whom disease severity could not be classified were excluded from further analysis.
The clinical features of participants at the time of enrolment are shown in Table 2. Infants with dengue did not present with specific clinical signs compared to patients with other febrile illnesses (OFI). Common features of upper respiratory tract viral infection, including running nose and cough, were observed with similar frequency in both groups, however diarrhea, vomiting and a petechial rash occurred more frequently in dengue patients than in infants with OFI. Fever was observed less frequently in dengue patients; however in some patients enrolled later in their illness, defervescence may have occurred prior to study enrolment.
The hematological findings and clinical manifestations during hospitalization in infants with primary dengue or other febrile illness are shown in Table 3 and Table 4. The median nadir in white blood cell (WBC) count in infants with dengue was significantly lower than that in infants with OFI (5600 vs 6100 cells/mm3, P = 0.035) and was primarily due to neutropenia. Liver transaminase levels were significantly higher in dengue cases (Table 3). In comparison with OFI cases, infants with dengue had lower platelet nadirs, greater hemoconcentration, petechiae, bruising, hepatomegaly and clinical evidence of systemic vascular leak (Table 4). The case fatality ratio was approximately 1% among dengue cases. One patient in the OFI group had shock and died of meningitis and pneumonia (Table 4).
Virological characteristics of infants with primary dengue
RT-PCR was performed on plasma samples collected at enrolment. In plasma samples from the 201 serologically-confirmed primary dengue patients, DENV was detected in 161 (80%). All four serotypes were detected: DENV-1 (66/161, 41%), DENV-2 (72/161, 44%), DENV-3 (22/161, 14%), and DENV-4 (2/161, 1%) (Table 5). The remaining 40/201 (20%) cases were aviraemic at the time of study entry. DENV-1 and DENV-2 were the dominant serotypes in this study population and accounted for 85% (137/161) of viraemic patients.
We compared disease severity in dengue patients infected with different DENV serotypes (Table 5). Although a greater proportion of DENV-2 infections resulted in DHF/DSS (91%) compared to the other serotypes (DENV-1 78%, p = 0.03; DENV-3 82%, p = 0.20; DENV-4 50%, p = 0.05), overall there was no significant association between DENV serotype and severity of disease when DHF and DSS were considered separately (p = 0.22). Four of the 134 infants who developed DHF/DSS were aviraemic at admission. Data on viraemia at enrolment was available for 118/201 infants with primary dengue. We compared viraemia at the time of study enrolment in infants with DF, DHF and DSS and found a non-significant trend towards higher viraemia with more severe disease (p = 0.1; Table 5). However, a limitation of our study was that we did not have samples collected in the first 48–72 hours of illness to be able to measure peak viraemia levels. Instead, we were limited to measuring viraemia at a time when in most patients it was already declining.
The concentration (ng/ml) of DENV NS1 antigen in infant plasma was measured at study enrolment (Table 5). At enrolment, 176/196 (89%) of dengue cases had detectable plasma NS1 levels. The NS1 concentration was significantly higher in DENV-1 and DENV-3 infections than in DENV-2 infections (p<0.001), and did not correlate with viraemia levels, which were similar among DENV serotypes (data not shown). We compared NS1 levels between primary dengue patients of different severities, stratified by DENV serotype (Figure 1). This showed a non-significant trend toward higher NS1 levels with increasing disease severity in those infants infected with DENV-3 or avireamic at admission (Chi-square test: p = 0.2, p = 0.1 respectively), but this trend was not observed in DENV-1 and DENV-2 infected patients.
Shown are the median, interquartile and 95th-percentile ranges of log10 NS1 concentration at enrolment, distributed by DENV serotypes and disease severity. Day of illness ranged from 3–9 and was comparable among DF, DHF, DSS groups. The number of patients in each group is shown in italics.
The sensitivity of dengue diagnostic tests in acute illness
The sensitivity of different dengue diagnostic approaches at the time of enrolment were compared to laboratory confirmation by serology on paired samples. NS1 detection was a sensitive approach (>80%) to diagnosing dengue in enrolment plasma samples collected on day 3, 4 or 5 of illness (Figure 2). The sensitivity of the NS1 test was significantly higher than real time RT-PCR in the first 6 days of illness (Chi-square test: p = 0.001). RT-PCR was sensitive early, but sensitivity declined with increasing illness duration. Conversely, IgM detection by MAC ELISA was only moderately sensitive on day 3 and 4, but detection improved with increasing duration of illness.
The number of patients evaluated on each day of illness is shown below the graph. Bars show the percentage of samples positive by each assay.
DENV neutralizing antibodies in maternal blood and relationship with age of disease onset
Plasma samples from 120 mothers of infants with primary dengue were available for PRNT50 assays, after excluding those women with serological evidence of recent DENV infection (n = 33), those with preterm babies (n = 19) and those mothers who did not provide paired blood samples (n = 29). Recent DENV infection was defined as a four-fold change in IgG to recombinant E protein in paired plasma samples or when any maternal plasma sample was IgM positive. Amongst the evaluated maternal plasma samples, 100% had neutralizing antibodies (PRNT50 assay) to at least one DENV serotype and 96% of mothers possessed neutralizing antibodies to ≥3 serotypes. The median titer of neutralizing antibody against DENV-4 was much lower than to the other 3 serotypes. The maternal neutralizing antibody titre to DENV1-4 was independent of maternal age (data not shown). Maternal neutralizing antibody titres against the serotype that infected each infant were compared to the infant's age at illness onset. There was only a limited correlation between maternal neutralizing antibody titres and the age at which infants present to hospital with symptomatic primary dengue (Figure S1).
This study describes the clinical and virological features of dengue in Vietnamese infants and is an extension of previous reports from our group . This report highlights the value of NS1 detection in the diagnosis of dengue in infants who otherwise present with non-specific clinical symptoms. Interestingly, we found DENV-2 infections to be associated with significantly lower plasma NS1 levels relative to DENV-1 or DENV-3 infections. Collectively, these data provide new insights into the pathogenesis of severe dengue in an age-group where diagnosis and management can be challenging.
The majority of infants hospitalized with dengue were between four and ten months of age and this is consistent with previous studies at this hospital and elsewhere in SE Asia , , . Infants with dengue initially presented with non-specific symptoms that included coryza, cough and diarrhea. Subsequently, many infants developed pathognomonic signs of DHF including petechiae, bleeding, bruising and vascular leak. Although the World Health Organization classification criteria were originally developed for older children, 97% of the infants with acute dengue in this study were adequately classified . Consistent with previous studies , , we demonstrate that DHF/DSS can occur during primary infection of infants. Surprisingly, the patients enrolled in our study had predominantly DHF grade II, with few cases having either DF or DSS. Consequently, we had little statistical power to detect differences in clinical or virological features between mild and severe cases. The limited breadth in our patient population was despite efforts to recruit patients with milder disease presentations by enrolling infants in the outpatients department of Children's Hospital No. 1.
The clinical signs and hematological manifestations in infants hospitalized with dengue were similar to those seen in children and adults , , , . Whole blood count results during hospitalization demonstrated leucopenia and elevated liver transaminases in infants with dengue compared to those with other febrile illnesses, however these differences are unlikely to be sufficient for differential diagnosis at the individual level. Infants with dengue were more likely to have hepatomegaly, petechiae and bruising than infants with other febrile illnesses. Clinical evidence of plasma leak (e.g. ascites) was observed in a minority of infants with DHF/DSS.
The average time to study enrolment since illness onset was 4–5 days. A disadvantage of not enrolling patients into the study earlier in their illness is that it was not possible to identify early risk factors for more severe outcomes e.g. DSS. One of the reasons few infants were enrolled into the study early in their illness relates to the standard of care at the hospitals where the study was conducted. Infants with fevers of just 1–2 days duration are often seen in the outpatient department, but most are treated as outpatients only with daily follow-up. For infants with DHF, only when the characteristic thrombocytopenia and a rising hematocrit are observed, usually on day 3 or 4, are those infants admitted to hospital. Specific dengue diagnostic tests such as PCR or NS1 assays are not routinely available.
By RT-PCR we were able to detect viraemia in 80% of the dengue cases. As supported by previous studies , we also found that the proportion of viraemic cases was highest in the first few days of illness. In this study, neither the viraemia nor antigenemia at enrolment correlated with disease severity, although a trend towards higher NS1 concentrations with increasing disease severity was observed in infants infected with DENV-3 or aviraemic at admission. However, our study participants were generally enrolled after 4–5 days of illness and therefore we probably have not measured the peak viraemia or NS1 antigenaemia. A greater proportion of DENV-2 infections resulted in DHF/DSS compared to other serotypes, however the number of DF and DSS cases was small and there was no significant association overall between infecting serotype and disease severity.
NS1 detection may be helpful in diagnosing dengue , , , . In this paper, we illustrated the superior sensitivity of DENV NS1 detection in comparison with two other dengue diagnostic tests (MAC ELISA and real-time RT-PCR), especially in the first few days after disease onset (≤4 days). Early diagnosis could assist clinical management by focusing attention on the clinically important features of dengue (capillary leakage) and minimizing unnecessary use of antibiotics. The sensitivity of NS1 detection was higher than RT-PCR during the first six days of illness, and many infants were still NS1 positive at the time of discharge from hospital. This is consistent with previous descriptions of the sensitivity of NS1 detection in children and adults with primary dengue , , . One of the reasons NS1 detection might be more sensitive in primary dengue is that the IgM/IgG response does not become measurable until day 6 or later. Previous studies in Vietnamese children demonstrated that a measurable anti-DENV IgG level in the test sample significantly reduced the likelihood of NS1 detection, possibly because of the immune complex formation between anti-NS1 IgG and soluble NS1 in the blood . Viraemia and NS1 antigenaemia appear to correlate closely early in infection, with divergence in the sensitivity of NS1 detection and RT-PCR from day four of illness (Figure 2). This may be due to more rapid degradation of viral RNA compared to NS1 protein. Our results support previous findings  of a lower concentration of NS1 antigen in DENV-2 infections, compared with other serotypes, and demonstrate that this is observed also in primary infections in infants as well as in secondary infections, with which DENV-2 is commonly associated. This could be due to the antibodies used in the NS1 ELISA having differential binding to DENV-2 NS1 protein compared with other serotypes and the limitation of using a DENV-2 NS1 protein standard for calibration of the quantitative assay used for all serotypes. This may have resulted in an overestimate of NS1 levels for DENV-1 and DENV-3, however our analysis of the association between NS1 antigenaemia and disease severity was stratified by serotype so is robust to this limitation. Alternatively, DENV-2 infections may result in less soluble NS1 protein due either to a greater tendency for immune complex formation with pre-existing IgG or to differences in viral infection between serotypes.
All of the mothers of infants with primary dengue in this study for whom plasma samples were available possessed DENV-neutralizing antibody, as measured by PRNT50. Neutralizing antibody, acquired passively by infants born to dengue-immune mothers, is suggested to provide protective immunity against dengue during the early months of life, but sub-neutralizing levels of maternal antibody are thought to be a factor in the pathogenesis of dengue in infants . We have recently demonstrated that the waning of maternal DENV-neutralizing antibody correlates temporally with the age of peak dengue burden in infants . Building on previous analyses  in a small subset of the current study population, we examined the relationship between maternal serotype-specific neutralizing antibody titre and infants' age at infection in individual mother-infant pairs, with the hypothesis that a higher PRNT50 titre in the mother may confer a longer period of protection in the infant. A weak positive correlation between maternal anti-DENV-2 PRNT50 titre and age at time of disease onset in infants with DENV-2 infections suggested higher maternal neutralizing antibody titres may be associated with a longer window of passively acquired immunity for DENV-2. However, no such correlation was found for DENV-1 or DENV-3. Our findings differ from recently reported observations of a strong positive correlation between maternal DENV-3 PRNT50 titre and infant age at the time of symptomatic DENV-3 infection . This difference may be partially attributable to several limitations to the current analysis. Maternal blood at infant admission is an imperfect proxy for infant's maternal antibody titre at birth as, although we excluded any mothers with serological evidence of recent dengue infection, we cannot exclude the possibility of DENV exposure and antibody boosting in the mothers since birth. For reasons of feasibility, and consistent with the work of others , we measured PRNT50 titres using prototype dengue viruses from each serotype, not viruses isolated from individual infected infants. Although these titres may therefore be an imperfect measure of in vivo DENV neutralizing capacity, we believe this to be a reasonable methodology based on the amino acid identity of the DENV E gene between the prototype viruses and dengue viruses isolated in southern Vietnam during the study period (mean 97.8% identity, range 96.3%–98.5% comparing prototype DENV of each serotype to 4 contemporary isolates of that serotype). An important consideration is the fact that the large majority (73%) of dengue cases in our study occurred after 6 months of age. We have reported previously that maternal dengue neutralizing antibody was undetectable (by PRNT50) in the majority of a healthy cohort of Vietnamese infants by 6 months of age, regardless of titre at birth . This suggests that after 6 months, infant age at dengue onset may be independent of PRNT50 titre at birth if few or no infants have remaining protection from maternal antibody. Further prospective studies of the relationship between passively acquired antibody and the spectrum of dengue infection and disease in infants can contribute to an improved understanding of immune correlates of protection against dengue, and a large prospective birth cohort study is currently underway in southern Vietnam to address these questions.
The data presented in this study highlight the challenges faced by clinicians in distinguishing infants with dengue from those with other febrile illnesses based on clinical and hematological signs alone, and thus identifying infants who may be at risk of developing severe dengue disease. Routine serology is an imperfect tool for the laboratory confirmation of dengue, particularly in the first 1–3 days of illness, and our results indicate that the addition of NS1 detection to the diagnostic algorithm has the potential to improve the early diagnosis of dengue in infants, as well as in older children and adults.
Maternal neutralizing antibody and infant age at dengue disease onset. Shown is the serotype-specific 50% plaque-reduction neutralization test (PRNT50) titre in maternal plasma versus the age of individual infants with primary infection with A) DENV-2 (N = 39), B) DENV-1 (N = 38), or C) DENV-3 (N = 14). Each point represents the titre of one mother-infant pair. Only maternal titres to DENV-2 were positively correlated with infant age (Spearman's rho = 0.3 (p = 0.03)).
(0.46 MB TIF)
Conceived and designed the experiments: CPS. Performed the experiments: TNBC SSW. Analyzed the data: TNBC SSW. Wrote the paper: TNBC KLA. Patient recruitment and collecting clinical information: LBL NTH LTMH NMT TTT LTP NTHT MNL. Director of the research unit: JJF.
- 1. PDVI (2009) Global burden of dengue. Pediatric dengue vaccine initiative. http://www.pdvi.org/about_dengue/GBD.asp.
- 2. Thein S, Aung MM, Shwe TN, Aye M, Zaw A, et al. (1997) Risk factors in dengue shock syndrome. Am J Trop Med Hyg 56: 566–572.
- 3. Graham RR, Juffrie M, Tan R, Hayes CG, Laksono I, et al. (1999) A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. studies in 1995–1996. Am J Trop Med Hyg 61: 412–419.
- 4. Halstead SB, Lan NT, Myint TT, Shwe TN, Nisalak A, et al. (2002) Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg Infect Dis 8: 1474–1479.
- 5. Chau TN, Quyen NT, Thuy TT, Tuan NM, Hoang DM, et al. (2008) Dengue in Vietnamese infants–results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J Infect Dis 198: 516–524.
- 6. Pengsaa K, Luxemburger C, Sabchareon A, Limkittikul K, Yoksan S, et al. (2006) Dengue virus infections in the first 2 years of life and the kinetics of transplacentally transferred dengue neutralizing antibodies in thai children. J Infect Dis 194: 1570–1576.
- 7. Nguyen TH, Nguyen TL, Lei HY, Lin YS, Le BL, et al. (2006) Volume replacement in infants with dengue hemorrhagic fever/dengue shock syndrome. Am J Trop Med Hyg 74: 684–691.
- 8. Nguyen TH, Lei HY, Nguyen TL, Lin YS, Huang KJ, et al. (2004) Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J Infect Dis 189: 221–232.
- 9. Hammond SN, Balmaseda A, Perez L, Tellez Y, Saborio SI, et al. (2005) Differences In Dengue Severity In Infants, Children, And Adults In A 3-Year Hospital-Based Study In Nicaragua. Am J Trop Med Hyg 73: 1063–1070.
- 10. Cardosa MJ, Wang SM, Sum MS, Tio PH (2002) Antibodies against prM protein distinguish between previous infection with dengue and Japanese encephalitis viruses. BMC Microbiol 2: 9.
- 11. WHO (1997) Dengue haemorrhagic fever- Diagnosis, treatment, prevention and control. 2nd ed. Geneva: World Health Organization.
- 12. Simmons CP, Popper S, Dolocek C, Chau TN, Griffiths M, et al. (2007) Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J Infect Dis 195: 1097–1107.
- 13. Simmons CP, Chau TN, Thuy TT, Tuan NM, Hoang DM, et al. (2007) Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis 196: 416–424.
- 14. Malavige GN, Velathanthiri VG, Wijewickrama ES, Fernando S, Jayaratne SD, et al. (2006) Patterns of disease among adults hospitalized with dengue infections. QJM 99: 299–305.
- 15. Kittigul L, Pitakarnjanakul P, Sujirarat D, Siripanichgon K (2007) The differences of clinical manifestations and laboratory findings in children and adults with dengue virus infection. J Clin Virol 39: 76–81.
- 16. de Oliveira Poersch C, Pavoni DP, Queiroz MH, de Borba L, Goldenberg S, et al. (2005) Dengue virus infections: comparison of methods for diagnosing the acute disease. J Clin Virol 32: 272–277.
- 17. Kumarasamy V, Wahab AH, Chua SK, Hassan Z, Chem YK, et al. (2007) Evaluation of a commercial dengue NS1 antigen-capture ELISA for laboratory diagnosis of acute dengue virus infection. J Virol Methods 140: 75–79.
- 18. Lapphra K, Sangcharaswichai A, Chokephaibulkit K, Tiengrim S, Piriyakarnsakul W, et al. (2008) Evaluation of an NS1 antigen detection for diagnosis of acute dengue infection in patients with acute febrile illness. Diagn Microbiol Infect Dis 60: 387–391.
- 19. Dussart P, Petit L, Labeau B, Bremand L, Leduc A, et al. (2008) Evaluation of Two New Commercial Tests for the Diagnosis of Acute Dengue Virus Infection Using NS1 Antigen Detection in Human Serum. PLoS Negl Trop Dis 2: e280.
- 20. Hang VT, Nguyet NM, Trung DT, Tricou V, Yoksan S, et al. (2009) Diagnostic Accuracy of NS1 ELISA and Lateral Flow Rapid Tests for Dengue Sensitivity, Specificity and Relationship to Viraemia and Antibody Responses. PLoS Negl Trop Dis 3: e360.
- 21. McBride WJ (2009) Evaluation of dengue NS1 test kits for the diagnosis of dengue fever. Diagn Microbiol Infect Dis.
- 22. Kliks SC, Nimmanitya S, Nisalak A, Burke DS (1988) Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38: 411–419.
- 23. Chau TN, Hieu NT, Anders KL, Wolbers M, Lien le B, et al. (2009) Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. J Infect Dis 200: 1893–1900.
- 24. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, et al. (2009) A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med 6: e1000171.